Prevention of SARS CoV 2 infection through development and clinical testing of a...
Prevention of SARS CoV 2 infection through development and clinical testing of a novel Virus Like Particle VLP vaccine
Our aim is to perform pre-clinical and clinical evaluation of a potential Wuhan Coronavirus vaccine candidate. The vaccine will be based on Virus-Like Particle (VLP) display of the SARS-CoV-2 Spike protein antigen. AdaptVac's VLP...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2020-114481RB-I00
DESARROLLO, FUNCION INMUNE Y EFICACIA DE CANDIDATOS VACUNALE...
484K€
Cerrado
FLU-MAL VLP
Chimeric Influenza VLP used as vaccine platform for presenta...
194K€
Cerrado
PRE2021-099058
DESARROLLO, FUNCION INMUNE Y EFICACIA DE CANDIDATOS VACUNALE...
101K€
Cerrado
EDUFLUVAC
Combinatorial immunization strategy to educate the immune sy...
6M€
Cerrado
PID2020-113184RB-C21
VACUNAS PEPTIDICAS, ESTRATEGIAS ANTIVIRALES Y MECANISMOS DE...
169K€
Cerrado
Información proyecto Prevent-nCoV
Duración del proyecto: 26 meses
Fecha Inicio: 2020-04-06
Fecha Fin: 2022-06-30
Líder del proyecto
KOBENHAVNS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Our aim is to perform pre-clinical and clinical evaluation of a potential Wuhan Coronavirus vaccine candidate. The vaccine will be based on Virus-Like Particle (VLP) display of the SARS-CoV-2 Spike protein antigen. AdaptVac's VLP display technology has been shown to significantly improve vaccine immunogenicity, longevity and efficacy, for a wide range of viral and parasite diseases in pre-clinical studies (including flu and malaria). A unique feature of the technology is its two-component approach. The VLP is generic to all vaccines, and produced at >1g/L yields using E. coli. The disease antigen is produced in any expression system, allowing the most challenging antigens to be successfully produced. The VLP and antigen is then simply mixed, and a spontaneous, irreversible, conjugation
occurs under physiological conditions. This results in site-specific, directional, and high-density display of the antigen on the VLP surface. The antigen will be produced using ExpreS2ion's Drosophila S2 insect cells based on the trimetric spike antigen. Furthermore, E. coli and baculovirus will be tested for Spike protein variants. The vaccine candidates will be tested pre-clinically using in vitro viral neutralization assays and possibly animal challenge
models as they become available at LUMC. ExpreS2ion will develop the production processes and transfer these for GMP manufacture of the VLP and vaccine antigen, outsourced, to AGC Biologics. Finally, a phase I/IIa study will be performed at Radboud University Medical Center in the Netherlands. A surrogate marker of protection will be established by showing protection in animal models using passive transfer of participant sera, or by in vitro SARS-CoV-2 viral neutralization. This project is focused on delivering a scalable vaccine, ready for testing in the field, which has been shown to be safe in humans and effective in in vitro or animal models.